Product category:
Contract research
News Release from: ClinPhone | Subject: Interactive voice response
Edited by the Laboratorytalk Editorial
Team on 12 November 2004
FDA OKs voice response in drug trials
Interactive voice response depression severity assessments are now acceptable to the US Food and Drug Administration in registration trials
The US Food and Drug Administration (FDA) has recently issued a statement regarding the acceptability of interactive voice response (IVR) self-report instruments that assess severity of illness in major depressive disorder and stated that these instruments are acceptable as primary endpoint data in pivotal clinical trials The assessments mentioned include the Hamilton Depression Rating Scale (HAMD), the Inventory of Depressive Symptomatology (IDS) and the Quick Inventory of Depressive Symptomatology (Qids)
This article was originally published on Laboratorytalk on 20 May 2003 at 8.00am (UK)
Related stories
The 'perfect' patient diary solution
Interactive voice response firm thinks clinical trials industry is not yet fully aware that interactive voice response is the most effective method of gathering patient diary information
IVR becomes 'favoured' patient diary technology
Interactive voice response increasingly seen as preferable to hand held devices for patient data collection services, says promoter of the system
The notification was issued in a letter to John Greist, CEO of Healthcare Technology Systems (HTS), an authority in the research, development and validation of computer administered clinical rating instruments.
Previously HTS had submitted evidence to the FDA on the effectiveness, validity and advantages of self-report assessments.
HTS's assessments for all pharmaceutical sponsored Phase I-IV trials are now delivered exclusively by ClinPhone.
Further reading
Clinphone eliminates common integration headaches
ClinPhone has launched its new combined electronic data capture (EDC) and interactive voice response/interactive web response (IVR/IWR) system
Partnership to accelerate patient recruitment
Companies join forces to transform the methods used by biopharmaceutical companies to contact, recruit and retain clinical trial patients
Although the FDA's comments regarding IVR are aimed primarily at research on depression, the statement promises to have far-reaching consequences in the clinical trials industry.
Already, the FDA has accepted IVR assessments for migraine, sleep, pain, social phobia and other disorders, and the list is expected to grow.
Pharmaceutical sponsors will now be able to choose IVR with the assurance that it has backing from the FDA.
This means that both pharmaceutical companies and their patients will be able to reap the benefits that IVR assessments deliver.
Implementing IVR offers several advantages over traditional methods.
In the past, patients were assessed by clinical interviewers, but the evidence suggests that there is substantial variability in assessments conducted by clinicians.
Further, studies have shown that interviewers may artificially inflate or deflate baseline scores to qualify patients for inclusion in a trial.
Using IVR, assessments are standardised and all questions are asked and scored consistently.
Additionally, IVR assessments perform error checking during interviews and offer immediate data storage and reduced costs.
Finally, patients can call into these automated systems as often as required by the protocol, even doing so from home.
Dr Greist commented, "This communication from FDA extends the use of the IVR HAMD beyond its widely recognised value in controlling rater score inflation at baseline to assessment over time where rater variability may adversely affect trial outcome. Request a free brochure from ClinPhone ...
"Further, accumulated evidence has shown that patient self-reports are accurate and regulators recognise the importance of the patient's perspective in evaluating drug efficacy.".
• ClinPhone: contact details and other news
• Email this article to a colleague
• Register for the free Laboratorytalk email newsletter
• Laboratorytalk Home Page
Search the Pro-Talk network of sites
